Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It would already be baked in their total market assumptions otherwise you are insinuating management is absolutely clueless. Probably similar to very simple question on call regarding investment & ROI. CEO couldn't answer an extremely basic strategic question.
It has everything to do with SequestOx. Simply put, if ER oxy isn't swiftly moving from reg to ADT version, this is real data that can extrapolate to IR ADT penetration.
ER ADT's are on the market. Why aren't all ER pharma sales ADT's now?
If this was even remotely true don't you think Nasrat would have stated we would be on the Nasdaq earlier than in 2 years at best? 100% of IR opiates is far from reality. Remember SequestOx only has a 400M market potential as stated by the CEO. I trust him and his team's due diligence.
I sure hope your comment is a joke. If not, your comment is so far out of whack.
I agree the timing is odd, especially after seeing Epic oxy payment
split. I don't think Nasrat knows any more than we do on SequestOx at this point. He did say there is a strong likelihood of delayed adcom. I think some are putting cart before the horse here.
I think it's a hedge. I don't think FDA news is coming this week.
I have also seen many companies do share offering right before a big decision in case it doesn't end well and the pps tanks. Timing is strange with all the cash they have on hand in addition to all the other dilution that has taken place since end of qtr.
Read Nasrat's words yourself or relisten to the conference call. Make your judgment call based on what management says, not what others here interpret.
Regardless, just a few week's left...
Hang in there. We all will know next steps soon. Remember this is an investment. When emotions get introduced, wrong investment decisions tend to be made.
Could get approval, but labeling may likely be delayed as Nasrat mentioned in the last call. I think that is exactly what we will hear on or before the 14th. We need ADF labeling and may not get that for a few months.
As I've stated before, nothing is ever certain with the FDA. Would be great if we didn't get a delay, signs are looking good, but there is no certainty. There are many faxts and many uncertainties that still exist. We all wait patiently over the next few weeks for next steps.
FDA writes their own rules. Remember, per Nasrat, the FDA has never seen tech like ours so there is no precedent.
We know very well the SequestOx rollout will not catch on to all pharmacies nationwide immediately. This will take time, especially if we stick with the Pura/Epic deal.
This is a cost+ deal so we'd get the manufacturing cost recovery + 50% split. We are blind to the manufacturing costs at this point. Plus, early on, they'll run into hiccups with manufacturing. It takes some time and experience to work the kinks out & start humming along achieving optimal mfg efficiencies.
From their 10K:
"All eligible patients receive ongoing savings through this program and will pay no more than $15 for a prescription of OXAYDO at all pharmacies."
This is $15, PER PRESCRIPTION, not PER PILL. I haven't researched Oxaydo enough on the frequency, but even at once/day for a 7-day IR prescription runs this at about $2/pill.
I think I saw in Egalet's 10k they were pricing at $15, but may be misremembering. Pricing will be interesting.
Not all addictions are created equal. Not everyone's biochemistry is the same. Many addictions can be overcome, but there is no free will when under the influence or when one's brain needs a substance. One cannot simply wave a magic wand and say I now want to be undrunk after several drinks. Free will gets removed and logical thought is thrown out the window.
I agree, will be interesting. SequestOx could get approval in a couple weeks, but if the labeling is delayed, sales get delayed until labeling is received. Much is still at stake. GL to you as well.
Yep, I stand corrected. Oxaydo is selling pretty piss poorly as well. Shows how vital the ADF labeling is as can be seen during their first full quarter with only $2.6M in total rev. Ouch.
You are exactly right. I was reading an old filing of theirs before FDA provided labeling guidance.
Isn't Oxaydo any Oxy ADF IR already on the market?
Millions?! Please explain. Their revenue from ops is annualizing at about $30,000 per year. Far cry from $100k let alone even $1 million.
Last comment on this as it is OT, but you are really off course here. We live in a much more complex globalized world. Shunning free trade, capital & labor flows will only hurt their economy in both near & long term. Career ending move by Cameron by promising to put it up for a referendum.
I would easily argue that in addiction, there is no free will. Addiction is not an option, it is a body's must have.
It's a way FDA can delay making a full decision. Sequest could be approved by July 14th, but FDA may postpone labeling decision until a later date. Need approval + ADT labeling to move forward.
Like I said, they are living in the past and can't conform to today's playing field. It will be to Europe's detriment. You will see.
No borders are 100% closed. This is today's reality. Glory days of decades ago is long gone and they can't adapt to the new norm.
Cash is received immediately. Revenue is recognized over life of agreement. Cash doesn't equal revenues. That help?
This is basic economics of economies of scale.
Sad day economically. EU countries could compete with China and the US, but they can't individually. They forgot that they learned that 20 years ago. History has been forgotten and thus will repeat itself.
Unbelievable. Never thought Britain would exit. Scotland stays. What a sad mess. Britain is paving way for others to follow suite.Will be too much for Germany to handle. Sad day for Europe's future.
Article was posted here previously and was released prior to horrible conference call or it would have had a much different tone.
Couch - but isn't this a multi-billion product? Nasrat says otherwise.
FDA pre-approved their trials & said they need to do another trial. Set them back another 2 years.
Don't you think if there was no competition that Nasrat would have stated that SequestOx potential of the 400M market would be 100% instead of as low as 1%?
Very well said & completely agree.
And for the hundreds of other companies that have done the same.
Everything is rainbows and puppy dogs here. Completely ignoring the recent conference call. Picking & choosing what they want to hear & ignoring what was said. Unbelievable!!
Never know what the FDA will approve. Why would a company spend millions and millions for drugs that never get approved. Doesn't add up.
Are you saying you are more aware of SequestOx market penetration than the CEO? Wow!!